Costim

Quick links to important sections

Costim

Treatment option: Infection, Cystic Fibrosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Costim

What is Costim? A Foundational Overview

Property Description
Active ingredient Colistimethate Sodium (Prodrug)
Form Sterile powder for solution
Pharmacological class Polymyxin-class Antibacterial
Common use Treating severe, drug-resistant bacterial infections
Origin Semi-synthetic (derived from Colistin)

What Type of Antibiotic is Costim?

Costim is the trade name for a potent, prescription-only medicine whose active compound is Colistimethate Sodium, classified as a specialized Polymyxin-class Antibacterial agent. This medication belongs to the family of polypeptide antibiotics and is primarily reserved for managing serious, multi-drug-resistant bacterial infections. It is considered a last-line antibiotic used predominantly to combat multi-drug-resistant (MDR) Gram-negative microorganisms that have failed to respond to more conventional therapies. Reserving this class for complex, life-threatening infections ensures its effectiveness is maintained where alternatives are exhausted.


Colistimethate Sodium: A Specialized Prodrug

The core of Costim's composition is Colistimethate Sodium, which functions as an inactive prodrug, meaning it requires conversion within the body to become therapeutically active. This semi-synthetic derivative is administered to the patient, where it undergoes hydrolysis in vivo to yield its true bactericidal form, Colistin (also known as Polymyxin E). This prodrug identity is a key feature, as it allows for the precise delivery of the highly potent agent. The active Colistin physically destroys bacteria through a detergent-like mechanism that disrupts the bacterial cell membrane, providing a direct method of bacterial elimination.


Dosage Forms and General Purpose

Costim is a single-ingredient product commonly supplied as a sterile powder for solution requiring reconstitution before use. This specialized preparation is designed to be prepared for both parenteral injection (intravenously or intramuscularly) and for inhalation as an aerosol. This dual-use preparation is a differentiating factor, allowing treatment for both systemic infections and localized infections, such as those that might occur in the lungs. The general therapeutic purpose of Costim is to provide a powerful, targeted means of overcoming severe infections caused by resistant bacteria when standard medical options are insufficient.

What side effects are possible with Costim?

Possible Side Effects and Safety Information

The official safety profile for Costim (Colistimethate Sodium) is heavily focused on the potential for nephrotoxicity (kidney damage) and neurotoxicity (nerve-related effects), which are the primary documented dose-limiting risks. Regulatory bodies classify these effects by frequency and system-organ class to structure the understanding of the medicine’s risk profile.


Adverse Reaction Scope

Category Description
Key Side Effects Nephrotoxicity and Neurotoxicity are the major dose-limiting risks.
Common Side Effects Nephrotoxicity (often reversible upon cessation), Paresthesia (tingling or numbness, particularly circumoral and facial), Dizziness, Vertigo, Slurred Speech, and non-specific Rashes or Pruritus.
System-Organ Classes Renal and Urinary Disorders, Nervous System Disorders, and Respiratory/Thoracic Disorders.
Serious Reactions Officially documented serious reactions include Acute Renal Failure, Apnea (respiratory arrest, especially with rapid IV administration), and Neuromuscular Blockade.

Safety Constraints and Patterns

The official labeling notes that Nephrotoxicity is a dose-dependent effect, often associated with cumulative dose and duration, while Neurotoxicity is frequently transient and may occur immediately following intravenous administration. Specific caution is advised for patients with impaired renal function due to a significantly higher risk of toxicity, and for individuals with conditions like Myasthenia Gravis because of the risk of exacerbating muscle weakness or apnea. Contraindication exists for patients with known hypersensitivity to the colistin drug class. Concomitant use with other nephrotoxic agents is officially discouraged due to an enhanced risk of adverse effects.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define overdosage of Colistimethate Sodium (Costim) as a serious, potentially fatal event, requiring immediate action.

Overdose Manifestations and Severe Outcomes:

The presentation of overdosage is primarily defined by severe systemic toxicity. Documented clinical manifestations include signs of neurotoxicity such as severe numbness or tingling (paresthesia), confusion, dizziness, slurred speech, and unsteadiness or ataxia. The most critical outcomes affect two main physiological systems: the renal system, resulting in acute renal insufficiency, and the neuromuscular system.

Overdosage can lead to significant muscle weakness and, most critically, apnea (cessation of breathing) or respiratory arrest resulting from neuromuscular blockade. Regulatory labeling notes that overdosage risk, specifically for apnea and neuromuscular blockade, is increased in the presence of impaired renal function.

Action Required:

Regulators mandate that individuals must seek emergency medical attention or contact a poison control center immediately for known or suspected overdosage. Treatment, as described in official sources, is by means of symptomatic and supportive treatment. Procedures such as hemodialysis or peritoneal dialysis may be employed to enhance drug clearance from the body.

Therapeutic Uses of Costim

What Costim Treats: Main Uses and Benefits

Costim is used in situations involving certain distressing symptoms and is relevant when supportive symptom management is appropriate. As a medication commonly associated with the Nonsteroidal Anti-Inflammatory Drug (NSAID) class, its use is generally relevant to the core therapeutic domains of this class.

The medication is commonly used across conditions presenting with acute episodes of discomfort and is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, including headache, dental pain, pain from musculoskeletal strain, and fever.

“It supports patients during difficult episodes by easing distress and assisting with maintaining functional stability.”

Costim contributes to easing the overall symptom load by being relevant for easing both pain and inflammation, as well as managing symptoms related to systemic imbalance like high temperature. It is often applied during phases of increased distress or discomfort associated with acute illness or minor injury recovery.

Quick Fact: Use in Symptom Clusters

Costim plays a role in managing symptoms where physical discomfort is combined with signs of inflammatory or irritative states, assisting with maintaining functional stability when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Official Regulatory Eligibility: Who Can and Cannot Use Costim?

This section details the population eligibility and restrictions for Costim (Colistimethate Sodium) as documented in governmental regulatory sources like the FDA and EMA.

Eligibility scope Official Regulatory Statements
Populations for whom use is allowed (as stated in label): Adults and Pediatric patients (including neonates) are generally eligible for use in severe infections [4.2].
Populations for whom use is contraindicated: Patients with a history of hypersensitivity (allergy) to Colistimethate Sodium, Colistin sulfate, or any agent in the Polymyxin B class must not use the medicine [1.1, 1.4].
Age-related eligibility rules: The medicine is approved for Adults and Pediatric patients. Geriatric patients require caution due to the consideration of age-related decline in renal function [4.3]. Caution is also advised for infants under 1 year of age as renal function is not fully mature [4.2].
Condition-specific eligibility rules: Impaired renal function is a critical restriction; use requires the greatest caution, and dosage adjustment is mandatory proportionate to the extent of impairment [1.4, 2.1]. Eligibility is also restricted for infections due to Proteus or Neisseria, as they are typically resistant [1.5].
Pregnancy and lactation eligibility status: Pregnancy: Use is restricted to cases where the potential benefit justifies the potential risk to the fetus (officially classified as Pregnancy Category C) [2.1]. Lactation: Use requires a decision to discontinue breastfeeding or therapy; caution is advised [2.1].
Eligibility-related restrictions: Use with extreme caution is mandated for patients with Myasthenia Gravis and Porphyria [2.4, 4.2]. The use of the inhaled formulation is restricted in patients with clinically significant haemoptysis [2.4].

Connection to the overall eligibility profile:

Regulatory documents strictly define who can and cannot use Costim by establishing absolute contraindications based on hypersensitivity to Polymyxins. For populations like those with impaired renal function or certain pre-existing comorbidities, eligibility is conditional, requiring the highest level of caution to manage documented risks according to official prescribing information.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Costim (Colistimethate Sodium) is established around two primary pharmacodynamic concerns and an effect on renal drug clearance.

Co-administration with curariform muscle relaxants or other agents such as ether and sodium citrate requires extreme caution. These substances are officially stated to potentiate the neuromuscular blocking effect of the medicine, which carries a documented risk of respiratory arrest. Similar caution is mandated when combining Costim with other Polymyxin or Aminoglycoside antibiotics due to additive effects.

The simultaneous use of Costim with any other potentially nephrotoxic medicinal product is associated with an increased risk of nephrotoxicity due to an additive toxic effect. Specific warnings involve an increased risk if co-administered with certain Cephalosporins. Additionally, the medicine may affect renal clearance, documented to decrease the excretion rate of numerous co-administered renally cleared drugs, which officially results in a higher serum level for the co-administered medicine.

A population-specific constraint is formally noted: the risk of neuromuscular blockade and apnea is heightened in patients with impaired renal function due to reduced drug clearance. Regulatory documents also state that no significant CYP enzyme interaction has been demonstrated in vitro.

Mechanism of Action

Costim, a T-cell engager (TCE) molecule, is designed to simultaneously bind two biological targets: a T-cell surface antigen, typically CD3 on the T-cell receptor (TCR) complex, and a target antigen expressed on a distinct cell population. This bivalent interaction type creates an immunological synapse, physically bridging the two cell types.

Furthermore, Costim integrates costimulatory domains, such as B7-2 and/or CD58 mimetics, into its structure. These domains act as agonists, directly engaging their respective T-cell costimulatory receptors, CD28 and CD2. This co-ligation, in conjunction with the CD3 engagement, delivers a dual-signal input into the T-cell. Intracellularly, CD3 ligation initiates the Lck-mediated phosphorylation of immunoreceptor tyrosine-based activation motifs (ITAMs) within the CD3zeta chain. The concurrent CD28 engagement activates the PI3 K/Akt/mTOR pathway, enhancing metabolic activity, while CD2/CD58 interactions stabilize the synapse structure and optimize signaling geometry. The downstream cascade involves the activation of transcription factors, including NF-kB and NFAT, leading to the transcription of genes for cell cycle progression and T-cell effector functions. This pathway modulation results in T-cell activation, robust proliferation, enhanced cytotoxic granule release, and cytokine production, collectively representing system-level physiological modulation of T-cell mediated cellular immunity.

Dosage and Administration Information

How Costim (Colistimethate Sodium) is Used

Costim, which contains the prodrug Colistimethate Sodium, is administered through specific labeled routes. For systemic infections, the medication is primarily given via Intravenous (IV) infusion or injection. For localized pulmonary infections, inhalation (nebulised solution or powder) is an approved method of delivery. The systemic administration frequency is typically daily, divided into two to four doses, often separated by six to twelve hours.

Official dosing is highly dependent on regional regulatory standards and the patient's physiological status. Doses are expressed either as Colistin Base Activity (CBA) in milligrams (US-aligned labels) or as International Units (IU or MIU) (EU-aligned labels), a critical distinction to prevent medication error. Standard adult maintenance doses range from 2.5 to 5.0 mg/kg/day CBA or 9 MIU/day. For critically ill patients, a loading dose is often required to achieve initial therapeutic levels quickly.

A key requirement is the mandatory dose adjustment for patients with any degree of renal impairment. The daily quantity must be reduced proportionally based on creatinine clearance. The sterile powder must be accurately reconstituted with Sterile Water for Injection and, if used intravenously, must be infused slowly over 30 to 60 minutes to comply with labeled procedural conditions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Costim

Costim (Colistimethate Sodium) is primarily reserved for specialized, serious bacterial infections. Due to this specialized role, the research base relies on a mix of different study types, including short-term clinical trials, broader reviews of patient data, and observational studies. Researchers and regulators have carefully explored the study designs and populations relevant to the medicine.

Evidence for Use in Severe Systemic Infections

Research exploring the use of intravenous Costim for severe systemic infections caused by multi-drug resistant (MDR) Gram-negative bacteria largely relies on observational cohort studies and detailed meta-analyses. These research scenarios are often conducted during periods of increased symptom activity in critically ill patients. Researchers examined outcomes related to physiological strain, such as measuring all-cause mortality at set intervals and monitoring clinical cure rates.

What remains uncertain is the optimal way to use the medicine—alone or in combination—because definitive comparative evidence is lacking from large-scale, controlled trials. Also, the follow-up durations were limited to the short term.

Evidence for Use in Chronic Pulmonary Infections (Inhaled)

The evidence supporting the use of inhaled Costim for chronic pulmonary infections (such as those caused by Pseudomonas aeruginosa) is based on Randomized Controlled Trials (RCTs). These long-term studies, often lasting 12 months, focused on outcomes like measuring changes in lung function and the annual rate of pulmonary exacerbations.

For patients with Cystic Fibrosis (CF), researchers reported measurements in key clinical outcomes between the treatment and control groups. However, for patients with Non-Cystic Fibrosis Bronchiectasis (NCFB), the findings were mixed and less consistent across studies.

What Remains Uncertain in the Research

Scientists and regulators agree that evidence quality varies across studies. The main areas where uncertainty exists include the lack of comparative evidence against newer antibiotics, and the fact that long-term effects are not fully established beyond the trial period. Subgroup findings are uncertain for many less common patient profiles, meaning the results apply only to the populations studied in the research so far.

Key Studies & References Colistimethate sodium is efficacious and safe for the management of sepsis in hematological diseases patients: a retrospective study

Frequently Asked Questions (FAQ)

Common questions about Costim (FAQ)

Q: Are the side effects of Costim usually temporary or long-lasting?

According to official product information, nephrotoxicity (kidney damage) is often described as reversible when the medicine is stopped. The neurotoxicity effects, such as tingling, dizziness, and slurred speech, are often noted as being transient (temporary) in official safety documents.

Q: Is Costim considered a short-term or a long-term medication?

The appropriate duration of use is typically determined by the specific condition being addressed. While the medicine is commonly used for short-term, severe systemic infections, official research has examined its use for localized pulmonary infections over long-term periods, sometimes lasting up to 12 months, according to study designs.

Q: Does Costim interact with common over-the-counter pain medications?

Official regulatory documents indicate that co-administering this medicine with certain common pain relievers, such as acetaminophen and aspirin, is documented as requiring caution. This is due to a documented potential for an increased risk of nephrotoxicity (kidney damage) or the possibility of higher serum levels of the pain medication.

Q: Can Costim be used safely by older adults?

Geriatric patients (older adults) are generally eligible for use. However, official regulatory documents specify that caution is indicated for this population. This is due to the importance of considering potential age-related decline in renal function, as this physiological factor is critical for determining appropriate administration conditions.

Q: Does Costim affect energy levels or cause insomnia?

The official safety profile notes that the medicine is associated with neurotoxicity effects. These can include dizziness, vertigo, and slurring of speech, which may affect a person's energy levels or ability to concentrate and coordinate. Insomnia (difficulty sleeping) is not listed as a commonly reported side effect.

Q: Does Costim interact with common vitamins or herbal supplements?

Regulatory documents report that no significant CYP enzyme interaction has been observed in laboratory studies (in vitro). However, the concomitant use of any other product, including vitamins or supplements that are potentially nephrotoxic (damaging to the kidneys), increases the documented risk of side effects.

Q: Are there specific symptoms that warrant calling a doctor immediately while taking Costim?

The official safety information lists serious reactions such as Acute Renal Failure, Apnea (respiratory arrest), and Neuromuscular Blockade. Signs of worsening kidney function, such as diminishing urine output, or any difficulty with breathing are identified in official documents as severe reactions that warrant prompt medical evaluation.

Q: What are the main things people commonly misunderstand about how Costim works?

Official sources emphasize two points that can sometimes be confused. First, the active compound is an inactive prodrug (Colistimethate Sodium) that requires conversion in the body to become active. Second, dosing is specified using two distinct measurements, either Colistin Base Activity (CBA) in milligrams or International Units (IU), a critical distinction noted in regulatory documents.

Q: What guidance is available about driving or operating machinery while using Costim?

Official guidance warns patients not to drive vehicles or use hazardous machinery during treatment. This is because the medicine may cause transient neurological effects. These effects include dizziness and slurring of speech, which can temporarily impair a patient's ability to operate equipment safely.

Q: Are there specific ethnic or population groups where Costim works differently?

The available research evidence indicates that subgroup findings are uncertain for many less common patient profiles. This means that the established results and effectiveness apply most directly to the specific patient populations that were included in the primary studies for the medicine.

Q: What are the most common reasons why patients are advised to stop taking Costim?

Official documentation recognizes that the development of signs of impaired renal function (nephrotoxicity) is a primary reason for discontinuation. These signs include diminishing urine output or increases in certain blood lab values (BUN/creatinine). If these occur, official guidance suggests that therapy is typically discontinued by a healthcare professional.

Q: What happens when Costim starts working in the body?

The active ingredient in the medicine, Colistimethate Sodium, is known as an inactive prodrug. This means it requires a process of chemical conversion (hydrolysis) once inside the body to become active. This process yields its active form, known as Colistin.

Q: How quickly should I expect to see the effects of Costim?

Following intravenous administration, the active form of the medicine achieves its peak concentration in the bloodstream very rapidly. This physiological peak concentration is reached approximately 10 minutes after the infusion is completed.

Q: What are the official warnings about using alcohol while on Costim?

Official guidance sourced from regulatory bodies advises patients to be careful when drinking alcohol during the period they are being administered this medicine. This is a general caution that should be discussed with a prescribing professional.

Q: What should be known about Costim's safety classification from regulatory agencies?

Official regulatory documents classify the medicine as Pregnancy Category C. This classification indicates that its use during pregnancy is formally restricted. It is only considered in cases where the potential benefit is judged to justify the potential risk to the developing fetus.

Q: How long after taking a dose does the effect of Costim typically peak?

Following intravenous administration, the active form of the medicine achieves its peak concentration in the bloodstream very rapidly. This physiological peak concentration is reached approximately 10 minutes after the infusion is completed.

Q: What official information exists regarding stopping Costim?

Official documentation addresses discontinuation mainly in the context of safety concerns. If signs of nephrotoxicity (kidney damage) occur, such as changes in laboratory values (BUN and creatinine), official documents advise that therapy should be discontinued immediately by a healthcare professional.

Q: What should a patient do if they accidentally take more Costim than expected?

Official documents note that signs of overdosage can include acute renal insufficiency (kidney function impairment), profound muscle weakness, and apnea (difficulty breathing). These are considered severe reactions for which prompt emergency medical attention is advised.

Q: Is Costim known to cause digestive issues like nausea or diarrhea?

The official safety labeling reports that Clostridium difficile associated diarrhea (CDAD) has been observed with this class of antibacterial agents. Additionally, some sources mention general upset tummy as a less serious side effect that may occur during treatment.

Q: Are there any requirements for regular lab tests while taking Costim?

Official guidance recommends monitoring kidney function regularly during treatment to detect early signs of nephrotoxicity. Furthermore, the medicine's serum level can be checked using a process called Therapeutic Drug Monitoring (TDM) in certain specific clinical situations.

Q: Is Costim known to interact with birth control pills?

The class of antibiotics to which this medicine belongs is generally classified by major public health bodies as having no restriction for use. This classification applies when the medicine is used in combination with combined hormonal contraception.

How should Costim be stored and disposed of?

How to Store and Dispose of Costim (Colistimethate Sodium)

Storage Requirements

Costim, supplied as a powder, must be stored under specific environmental conditions to maintain stability. The unreconstituted powder requires storage at room temperature, below 25 C (77 F), and must not be refrigerated or frozen. The medicine must be kept in its original outer carton and the vial kept tightly closed to protect it from light and moisture.

Stability and Disposal

Once the powder is reconstituted into a solution, its storage rules change; the solution is stable for a maximum of 24 hours when stored in the refrigerator (2 C to 8 C). Any unused or expired medicine must be kept out of the sight and reach of children.

For disposal, medicines must not be discarded via wastewater or household garbage. Unused product must be returned to a pharmacist or a local regulated collection program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Costim found in:

A-Z Index: